L-dopa in the treatment of Parkinson's disease
Völler, G.
Die Medizinische Welt 27: 1267-1268
1970
ISSN/ISBN: 0025-8512 PMID: 5512643 Document Number: 24472
Document emailed within 1 workday
Related Documents
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Figuerido, J.A.; De la Herrán, J. 1970: Personal experience in the treatment of Parkinson's disease with L-Dopa Revista Clinica Espanola 119(6): 555-562
Barbeau, A.; Gillo-Joffroy, L.; Mars, H.; Arsenault, A. 1972: Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602 Revue Canadienne de Biologie 31(Suppl): 169-174
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Broussolle, E. 2000: Dopa-therapy in the treatment of early stage Parkinson's disease Revue Neurologique (Paris) 156(2 Part 2): 91-97
Sigwald, J.; Raymondeaud, C. 1970: Abnormal movements observed during treatment of Parkinson's disease with L-dopa Revue Neurologique (Paris) 122(2): 103-112
Dzudza, M.; Dzudza, D. 1974: Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease Medicinski Arhiv 28(4): 407-415
Casacchia, M.; Barba, C.; Ruggieri, S.; Zamponi, A.; Agnoli, A. 1974: Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination Rivista di Neurologia 44(5): 303-330
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Glasgow, G.L.; Henley, J.W.; Willoughby, E.W. 1974: L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease Australian and New Zealand Journal of Medicine 4(4): 373-378
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Henry, P.; Lacut, J.Y.; Pouget-Abadie, J.; Bergouignan, M.; Leng-Lĕvy, J. 1971: One year of experience with L-Dopa in Parkinson's disease Bordeaux Medical 4(5): 1581-1591